Abstract 108P
Background
Fusion represents an important type of somatic alterations which promote oncogenesis and serve as a diagnostic and targeted marker in cancers. This study aims to identify the landscape of fusions in Chinese patients with solid tumors and expand our understanding of druggable fusions, together providing valuable information for therapeutics decision making.
Methods
Tumor/plasma samples (n = 19251) were assayed hybrid capture-based next-generation sequencing (NGS). Results were analyzed to determine the frequency of common and rare fusion and variant detection.
Results
A total of 719 fusion events (3.73% of 19251) were identified, including 458 common fusions and 261 rare fusions. A majority (1.77%) of tumors had ALK fusions, followed by 0.49%, 0.33%, 0.20%, 0.16%, 0.14%, 0.10% and 0.09% with RET, ROS1, TMPSS2, EWSR1, FGFR1/2/3, BRAF and NRTK1/2/3 fusions, respectively. Among the fusions identified, the distribution across tumor types was as follows: prostate cancer (5.90%), non-small cell lung cancer (NSCLC, 4.71%), bladder cancer (4.40%), kidney cancer (3.60%), gallbladder cancer (3.27%), gastric cancer (2.31%), hepatocellular carcinoma (1.96%), Bowel cancer (1.10%) and other (1.55%). The most commonly rearranged kinases were ALK (63.82%, 321/503), RET (17.10%, 86/503) and ROS1 (10.34%, 52/503) in NSCLC, TMPRSS2 (73.47%, 36/49) in prostate cancer, EWSR1 (71.43%, 10/14) in sarcoma, and FGFR3(37.5%, 9/24) in bladder cancer. ALK fusions were detected in 5.87% (20/341) of fusion+ non-NSCLC cases. Meanwhile, NTRK fusions were observed in 8 cancer types. In the mixed cancer cohort, double-fusion variant events were observed in 6.4% of patients with fusions.
Conclusions
Our data have depicted a comprehensive overview of the landscape of fusions across a wide variety of cancer types, which helps recognize potentially druggable fusions and translate into therapeutic applications.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Li, Y. Zhang, X. Liang, F. Lou, S. Cao, H. Wang: Financial Interests, Personal, Full or part-time Employment: AcornMed Biotechnology Co. Ltd.